UBS raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $441 from $411 and keeps a Buy rating on the shares. A big Rezdiffra beat in Q3 shows an underappreciated opportunity in nonalcoholic steatohepatitis, and ESSENCE could also be a clearing event, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- Madrigal Pharmaceuticals Reports Strong Rezdiffra Launch
- Madrigal Pharmaceuticals price target raised to $394 from $377 at Canaccord
- Madrigal Pharmaceuticals reports Q3 EPS ($4.92), consensus ($6.91)
- Madrigal Pharmaceuticals to present multiple resmetirom data presentations
- MDGL Upcoming Earnings Report: What to Expect?
Questions or Comments about the article? Write to editor@tipranks.com